Literature DB >> 27986662

A pathogenic role of complement in arterial hypertension and hypertensive end organ damage.

Ulrich O Wenzel1,2, Marlies Bode3, Jörg Köhl4,5, Heimo Ehmke6,2.   

Abstract

The self-amplifying cascade of messenger and effector molecules of the complement system serves as a powerful danger-sensing system that protects the host from a hostile microbial environment, while maintaining proper tissue and organ function through effective clearance of altered or dying cells. As an important effector arm of innate immunity, it also plays important roles in the regulation of adaptive immunity. Innate and adaptive immune responses have been identified as crucial players in the pathogenesis of arterial hypertension and hypertensive end organ damage. In line with this view, complement activation may drive the pathology of hypertension and hypertensive injury through its impact on innate and adaptive immune responses. It is well known that complement activation can cause tissue inflammation and injury and complement-inhibitory drugs are effective treatments for several inflammatory diseases. In addition to these proinflammatory properties, complement cleavage fragments of C3 and C5 can exert anti-inflammatory effects that dampen the inflammatory response to injury. Recent experimental data strongly support a role for complement in arterial hypertension. The remarkably similar clinical and histopathological features of malignant nephrosclerosis and atypical hemolytic uremic syndrome, which is driven by complement activation, suggest a role for complement also in the development of malignant nephrosclerosis. Herein, we will review canonical and noncanonical pathways of complement activation as the framework to understand the multiple roles of complement in arterial hypertension and hypertensive end organ damage.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  C1q; C3aR; C5aR1; C5aR2; arterial hypertension; complosome

Mesh:

Substances:

Year:  2016        PMID: 27986662     DOI: 10.1152/ajpheart.00759.2016

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  15 in total

Review 1.  Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases.

Authors:  Elena Bartoloni; Alessia Alunno; Roberto Gerli
Journal:  Nat Rev Cardiol       Date:  2017-08-24       Impact factor: 32.419

Review 2.  Role of Inflammatory Diseases in Hypertension.

Authors:  E Bartoloni; A Alunno; V Valentini; F Luccioli; E Valentini; G La Paglia; O Bistoni; Roberto Gerli
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-06-09

Review 3.  Salt, inflammation, IL-17 and hypertension.

Authors:  Ulrich O Wenzel; Marlies Bode; Christian Kurts; Heimo Ehmke
Journal:  Br J Pharmacol       Date:  2018-06-15       Impact factor: 8.739

4.  Clinical Value of Complement Activation Biomarkers in Overt Diabetic Nephropathy.

Authors:  Karyne Pelletier; Arnaud Bonnefoy; Hugo Chapdelaine; Vincent Pichette; Matthieu Lejars; François Madore; Soumeya Brachemi; Stéphan Troyanov
Journal:  Kidney Int Rep       Date:  2019-03-20

5.  Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy.

Authors:  Ludwig Haydock; Alexandre P Garneau; Laurence Tremblay; Hai-Yun Yen; Hanlin Gao; Raphaël Harrisson; Paul Isenring
Journal:  J Mol Med (Berl)       Date:  2021-10-29       Impact factor: 4.599

Review 6.  Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic?

Authors:  Meena S Madhur; Fernando Elijovich; Matthew R Alexander; Ashley Pitzer; Jeanne Ishimwe; Justin P Van Beusecum; David M Patrick; Charles D Smart; Thomas R Kleyman; Justin Kingery; Robert N Peck; Cheryl L Laffer; Annet Kirabo
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

7.  Acute kidney injury successfully treated with autologous granulocyte colony-stimulating factor-mobilized peripheral blood CD34-positive cell transplantation: A first-in-human report.

Authors:  Hiroyuki Suzuki; Takayasu Ohtake; Toshitaka Tsukiyama; Marie Morota; Kunihiro Ishioka; Hidekazu Moriya; Yasuhiro Mochida; Sumi Hidaka; Tsutomu Sato; Takayuki Asahara; Shuzo Kobayashi
Journal:  Stem Cells Transl Med       Date:  2021-05-06       Impact factor: 6.940

8.  What is the impact of blood pressure on neurological symptoms and the risk of ESKD in primary and secondary thrombotic microangiopathies based on clinical presentation: a retrospective study.

Authors:  Jean-Michel Halimi; Benjamin Thoreau; Florent von Tokarski; Adeline Bauvois; Juliette Gueguen; Nicolas Goin; Christelle Barbet; Sylvie Cloarec; Elodie Mérieau; Sébastien Lachot; Denis Garot; Adrien Lemaignen; Emmanuel Gyan; Franck Perrotin; Claire Pouplard; François Maillot; Philippe Gatault; Bénédicte Sautenet; Emmanuel Rusch; Véronique Frémeaux-Bacchi; Cécile Vigneau; Guillaume Bayer; Fadi Fakhouri
Journal:  BMC Nephrol       Date:  2022-01-20       Impact factor: 2.388

9.  Kinin B1 Receptor Mediates Renal Injury and Remodeling in Hypertension.

Authors:  Debargha Basuli; Rohan Umesh Parekh; Acacia White; Abdullah Thayyil; Srinivas Sriramula
Journal:  Front Med (Lausanne)       Date:  2022-01-18

10.  RNA sequencing reveals induction of specific renal inflammatory pathways in a rat model of malignant hypertension.

Authors:  Carlos Menendez-Castro; Nada Cordasic; Fabian B Fahlbusch; Arif B Ekici; Philipp Kirchner; Christoph Daniel; Kerstin Amann; Roland Velkeen; Joachim Wölfle; Mario Schiffer; Andrea Hartner; Karl F Hilgers
Journal:  J Mol Med (Berl)       Date:  2021-09-15       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.